NCT00659048已完成3 期
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 106
- 试验地点
- 1
- 主要终点
- 24 h plasma cortisol profiles and urinary cortisol
研究概览
简要总结
The primary objective of this study is to demonstrate that there are no clinically relevant additive inhibitory effects on the HPA-axis when ciclesonide nasal spray is concomitantly administered with orally inhaled HFA-BDP. The secondary objectives are to evaluate safety and tolerability of the combined dosing regimen of orally inhaled HFA-BDP and ciclesonide nasal spray.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18 - 60 years of age.
- •General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the trial.
- •A history of PAR for a minimum of one year immediately preceding the Screening Visit.
- •A demonstrated sensitivity to at least one allergen known to induce PAR through a standard prick or intradermal test. A positive test is defined as a wheal diameter at least 3 mm larger than the control wheal for the prick test, and 7 mm or greater than the control for the intradermal test. Documentation of a positive result within 12 months prior to the Screening Visit is acceptable.
- •Females of child-bearing potential are currently taking and will continue to use a medically reliable method of contraception for the entire study duration (e.g. oral, injectable, trans-cutaneous or implantable contraceptives or intrauterine devices or double-barrier protection). Women of childbearing potential, or less than 1 year postmenopausal, will require a negative plasma pregnancy test at the Screening Visit as well as at last on-treatment visit.
- •Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and compliance with all study requirements (visits, record keeping, etc).
- •Normal body weight as evidenced by a Body Mass Index (BMI) between ³ 18 and 31 kg/m², and a body weight > 45 kg.
排除标准
- •Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the study period.
- •History or physical findings of nasal pathology, including nasal polyps (within the last 60 days) or other clinically significant respiratory tract malformations, recent nasal biopsy (within the last 60 days), nasal trauma, or surgery and atrophic rhinitis or rhinitis medicamentosa (within the last 60 days).
- •Participation in any investigational drug trial within the 30 days preceding the Screening Visit (S0).
- •A known hypersensitivity to any corticosteroid or any of the excipients in the formulations.
- •History or current evidence of clinically relevant allergies or idiosyncrasy to drugs or food.
- •History of alcohol or drug abuse within the preceding two years.
- •History of a positive test for HIV, hepatitis B or hepatitis C.
- •Use of any prohibited concomitant medications within the prescribed (per protocol) withdrawal periods prior to the Screening Visit (S0) and during entire study duration.
- •Previous participation in an intranasal ciclesonide study.
- •Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding the Screening Visit (S0).
- •Exposure to corticosteroids for any indication, chronic or intermittent (e.g.: asthma, contact dermatitis), during the past 2 months, or presence of an underlying condition that can reasonably be expected to require treatment with corticosteroids during the course of the study.
- •Use of topical corticosteroids in concentrations in excess of the equivalent of 1% hydrocortisone for dermatological conditions during the past 1 month, or presence of an underlying condition that can reasonably be expected to require treatment with such preparations during the course of the study.
- •Clinically relevant abnormalities in clinical chemical, hematological or any other laboratory variables.
- •Chronic or clinically relevant acute infections.
- •Vegetarian diet or other unusual dietary habits that would preclude the subject's acceptance of standardized meals.
- •Blood donation within the last 30 days before start of the study.
- •Patients that do not have regular sleep patterns (e.g. working at night and sleeping during the daylight hours).
- •Active asthma requiring treatment with inhaled or systemic corticosteroids; intermittent use of beta agonists is acceptable.
- •History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, the common cold, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)] within the 14 days preceding the Screening Visit (S0), or development of a respiratory infection during the Run-in Period.
- •Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit (S0). Low doses of antibiotics taken for prophylaxis are permitted if the therapy was started prior to the Screening Visit (S0) AND is expected to continue throughout the trial.
- •Initiation of immunotherapy during the study period or dose escalation during the study period. However, initiation of immunotherapy 90 days or more prior to the Screening Visit (S0) AND use of a stable (maintenance) dose (30 days or more) may be considered for inclusion.
- •Failure to adequately understand and comply with the HFA-BDP instructions or failure to properly administer study medication.
研究组 & 干预措施
1
Active Comparator
Ciclesonide 200µg
干预措施: Ciclesonide (Drug)
2
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
24 h plasma cortisol profiles and urinary cortisol
时间窗: 53 days
次要结局
- 24-hour urinary cortisol will be monitored at the following times(53 days)
- Adverse events(53 days)
- vital signs(53 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
The study of having an inhibitory effect on occuring ocular surface disorders of Blokyleate PF ophthalmic solution 2% in a glaucomatous eye -Controlled trial with Mikelan ophthalmic solution 2%Primary open-angle glaucoma which is in a limited sense, normal tension glaucoma, primary angle-closure glaucoma, exfoliation glaucoma, or high-tension glaucomaJPRN-UMIN000003214ITTEN Pharmaceutical co. ltd.150
已完成
不适用
Colonisation of the nasopharynx with BLIS K12 and inhibition of growth of pathogens in healthy adult volunteers.otitis mediaACTRN12619000779178BLIS technologies50
尚未招募
1 期
Exploratory Investigation of the Inhibitory Effect of Codium fragile Extract Lectin on Biofilm Formation on Human Tooth SurfaceOral Biofilm InfectionJPRN-UMIN000053076Okayama University15
已完成
2 期
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid TumorsMalignant Solid TumorNCT01515306Eli Lilly and Company48
已完成
不适用
The retrospective clinical study on inhibitory effect of 0.1% brimonidine ophthalmic solution against the optic disc hemorrhageJPRN-UMIN000026406Fukui-ken Saiseikai Hospital40